Clinical Trial Update: NG2 and DLL3 CAR-T Cells Targeting Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating NG2-targeted and DLL3-targeted CAR-T cells for melanoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DLL3 CAR-T cells
• NG2 CAR-T cells

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: RECRUITING